How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,083 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery (PubMed)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery In the US, obesity rates are increasing greatly. The Centers for Disease Control and Prevention estimates that 68.5% of Americans, including 63.9% of adult women older than 20 years, are overweight (body mass index between 25 kg/m2 and 29.9 kg/m2) or obese (body mass index >30 kg/m2). In light of this, it is not surprising that the rates of bariatric surgery have also been increasing. When considering the metabolic

Full Text available with Trip Pro

2016 Open access journal of contraception

2. CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition

CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015) - Faculty of Sexual and Reproductive Healthcare CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015) CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015) Share

2015 Faculty of Sexual & Reproductive Healthcare

3. Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers

Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03255941 Recruitment Status : Completed First Posted : August 21, 2017 Last Update Posted : February 15, 2019

2017 Clinical Trials

4. Depo Provera

Depo Provera Depo Provera Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Depo Provera Depo Provera Aka: Depo Provera , Depot (...) Consider low dose supplemental for 1-2 weeks Consider pharmacologic adjuncts 800 mg PO tid for 1-2 weeks Supplemental for 1-2 weeks Premarin 0.625 to 1.25 qd 20 ug qd Estradiol (Estrace) 0.5 to 1 mg qd Consider low dose for 2-3 months If above measures fail Do not increase Depo dose (lowers efficacy) Weight gain Weight gain often exceeds 3 pounds Weight gain may be persistent and excessive Depo Provera may not be best option for obese patient Future fertility Fertility returns 7-12 months after last

2018 FP Notebook

5. Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera (PubMed)

Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera Molar pregnancies represent an uncommon yet important obstetric problem with potentially fatal outcomes. Patients typically present with signs and symptoms of early pregnancy, and physicians most often suspect nonmolar pregnancy complications initially; however a hydatidiform mole should be included in the differential diagnosis of a woman with a positive pregnancy test and abnormal vaginal bleeding irrespective (...) of the use of contraception. Our case is that of an adolescent female on Depo-Provera injectable contraceptive with increased vaginal bleeding, abdominal pain, nausea, and vomiting who was incidentally found to be pregnant and subsequently diagnosed with a molar pregnancy despite persistent denial of having initiated sexual intercourse. Though gestational trophoblastic disease is uncommon with an incidence of about 1-2 cases per 1,000 pregnancies, a clinician has to display a high index of suspicion when

Full Text available with Trip Pro

2016 Case reports in obstetrics and gynecology

6. Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia. (PubMed)

Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia. The objective of this study was to assess effectiveness and safety of Depo-Provera (medroxyprogesterone acetate) in treatment of endometrial hyperplasia (EH) and to compare it with norethisterone acetate (NETA) as an oral progestogen treatment. One hundred forty six women aged 35 to 50 years with abnormal uterine bleeding and diagnosed as having EH were randomized to receive either Depo-Provera (...) , one injection every 3 months for 6 months (2 doses), or oral cyclic NETA, 15 mg daily for 14 days per cycle for 6 months. Primary outcome measure was regression of EH. Secondary outcome variables were side effects of treatment, persistence/progression of EH during follow-up period. After 6 months of treatment, Depo-Provera was more successful in achieving regression of nonatypical EH than NETA (67 [91.8%] of 73 women vs 49 [67.1%] of 73, respectively), and the difference between the 2 groups

2016 Reproductive sciences (Thousand Oaks, Calif.) Controlled trial quality: predicted high

7. Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood

Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood (DSAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02509767 Recruitment Status : Active, not recruiting First Posted : July

2015 Clinical Trials

8. Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda

Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01578447 Recruitment Status : Completed First Posted : April

2012 Clinical Trials

9. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. (PubMed)

Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system, could potentially improve and expand contraceptive injection services, but acceptability of SP is unknown. HIV-positive women need contraception to avoid unintended pregnancy and risk of vertical HIV transmission. We assessed

2014 Contraception Controlled trial quality: uncertain

10. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. (PubMed)

Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system, could potentially improve and expand contraceptive injection services, but acceptability of SP is unknown. HIV-positive women need contraception to avoid unintended pregnancy and risk of vertical HIV transmission. We assessed

2014 Contraception Controlled trial quality: uncertain

11. Is there a causal association between lipodystrophy and depo provera injections?

Is there a causal association between lipodystrophy and depo provera injections? Is there a causal association between lipodystrophy and depo provera injections? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there a causal association between lipodystrophy and depo provera injections? ATTRCT has found no literature discussing an association between depo provera and lipodystrophy. Answered 5 July 2012 Follow us: © 2019 Trip Database

2012 TRIP Answers

12. In a patient with a contraindication to the combined pill, can the bleeding side-effects of Depo-provera be managed with intermittent short courses of norethisterone and is it safe (given they are con

In a patient with a contraindication to the combined pill, can the bleeding side-effects of Depo-provera be managed with intermittent short courses of norethisterone and is it safe (given they are con In a patient with a contraindication to the combined pill, can the bleeding side-effects of Depo-provera be managed with intermittent short courses of norethisterone and is it safe (given they are contraindicated for COC)? - Trip Database or use your Google+ account Liberating the literature ALL (...) @tripdatabase.com In a patient with a contraindication to the combined pill, can the bleeding side-effects of Depo-provera be managed with intermittent short courses of norethisterone and is it safe (given they are contraindicated for COC)? The Faculty of Sexual and Reproductive Healthcare published Management of Unscheduled Bleeding in Women Using Hormonal Contraception in 2009 [1]. Page 5 has a chart showing options for women with unscheduled bleeding based on a variety of hormonal contraceptive methods

2011 TRIP Answers

13. Does the depo-provera contraceptive injection cause abnormal or borderline smears?

Does the depo-provera contraceptive injection cause abnormal or borderline smears? Does the depo-provera contraceptive injection cause abnormal or borderline smears? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Does the depo-provera contraceptive injection cause abnormal or borderline smears? ATTRACT found very little information with which to answer this question. However, the summary of product characteristics (SPC) (1) for depo-provera

2011 TRIP Answers

14. Prospective, Multi-center Randomized Intermediate Biomarker Study of Oral Contraceptive vs. Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome. (PubMed)

Prospective, Multi-center Randomized Intermediate Biomarker Study of Oral Contraceptive vs. Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome. Women with Lynch syndrome have a 40% to 60% lifetime risk for developing endometrial cancer, a cancer associated with estrogen imbalance. The molecular basis for endometrial-specific tumorigenesis is unclear. Progestins inhibit estrogen-driven proliferation, and epidemiologic studies have shown that progestin-containing oral (...) contraceptives (OCP) reduce the risk of endometrial cancer by 50% in women at general population risk. It is unknown whether they are effective in women with Lynch syndrome. Asymptomatic women ages 25 to 50 with Lynch syndrome were randomized to receive the progestin compounds Depo-Provera (depo-MPA) or OCP for three months. An endometrial biopsy and transvaginal ultrasound were conducted before and after treatment. Endometrial proliferation was evaluated as the primary endpoint. Histology and a panel

Full Text available with Trip Pro

2013 Cancer prevention research (Philadelphia, Pa.) Controlled trial quality: uncertain

15. Please can you let me know if Depo Provera is a contraception that should be used for a long time. And should women of older age 40 to 50 + be using the depo provera as they will be at risk of menapau

Please can you let me know if Depo Provera is a contraception that should be used for a long time. And should women of older age 40 to 50 + be using the depo provera as they will be at risk of menapau Please can you let me know if Depo Provera is a contraception that should be used for a long time. And should women of older age 40 to 50 + be using the depo provera as they will be at risk of menapause and osteoperosis? - Trip Database or use your Google+ account Find evidence fast ALL (...) @tripdatabase.com Please can you let me know if Depo Provera is a contraception that should be used for a long time. And should women of older age 40 to 50 + be using the depo provera as they will be at risk of menapause and osteoperosis? The CKS guideline on contraception (1) notes on duration: “The license does not restrict the duration of use (apart from recommending that the risks and benefits of continued use be reviewed after 2 years).” The NICE guideline on long-acting reversible contraception (2

2010 TRIP Answers

16. Depo Provera

Depo Provera Depo Provera Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Depo Provera Depo Provera Aka: Depo Provera , Depot (...) Consider low dose supplemental for 1-2 weeks Consider pharmacologic adjuncts 800 mg PO tid for 1-2 weeks Supplemental for 1-2 weeks Premarin 0.625 to 1.25 qd 20 ug qd Estradiol (Estrace) 0.5 to 1 mg qd Consider low dose for 2-3 months If above measures fail Do not increase Depo dose (lowers efficacy) Weight gain Weight gain often exceeds 3 pounds Weight gain may be persistent and excessive Depo Provera may not be best option for obese patient Future fertility Fertility returns 7-12 months after last

2015 FP Notebook

17. Lower Dose Depo Provera® Contraceptive Injection

Lower Dose Depo Provera® Contraceptive Injection Lower Dose Depo Provera® Contraceptive Injection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lower Dose Depo Provera® Contraceptive Injection The safety (...) -center, parallel-group study to evaluate and compare the PD and PK of MPA after a single SC injection of either 45 mg/0.3 mL, 75 mg/0.5 mL or 105 mg/0.7 mL of Depo-Provera CI, and one cycle of Depo-subQ 104 use when injected in the abdomen, in women of reproductive age with confirmed ovulatory baseline cycle Condition or disease Intervention/treatment Phase Contraception Drug: Depo-Provera CI Drug: Depo-subQ 104 Phase 1 Detailed Description: This is a randomized, partially-blinded, multi-center

2016 Clinical Trials

18. Is there any evidence for DEXA scanning in patients on depo provera

Is there any evidence for DEXA scanning in patients on depo provera Is there any evidence for DEXA scanning in patients on depo provera - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence for DEXA scanning in patients on depo provera The Faculty of Family Planning and Clinical Effectiveness Unit (FFPRHC) answered a query on the most recent advice concerning bone mineral density and the use of depot-medroxyprogesterone acetate

2010 TRIP Answers

19. Depo-Provera

Depo-Provera Medroxyprogesterone acetate - Wikipedia Medroxyprogesterone acetate From Wikipedia, the free encyclopedia (Redirected from ) Not to be confused with , a natural and bioidentical progestogen. Medroxyprogesterone acetate Clinical data Pronunciation Provera, Depo-Provera, Depo-SubQ Provera 104, Curretab, Cycrin, Farlutal, Gestapuran, Perlutex, Veramix, others Synonyms MPA; DMPA; Methylhydroxy progesterone acetate; Methylacetoxy progesterone; MAP; Methypregnone; Metipregnone; 6α-Methyl (...) 34 O 4 386.532 g/mol g·mol −1 3D model ( ) C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C InChI=InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1 Key:PSGAAPLEWMOORI-PEINSRQWSA-N Medroxyprogesterone acetate ( MPA ), also known as depot medroxyprogesterone acetate ( DMPA ) and sold under the brand name Depo-Provera among others, is a of the type

2012 Wikipedia

20. What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even i

to use additional contraception or avoid sex for the next 7 days. The need for emergency contraception should be assessed individually.” In December 2009 TRIP Answers answered a similar question as to whether the duration of repeat depo provera had been extended to thirteen and a half weeks (2). We have provided a link to the answer below. 1. 2. Answered 28 April 2010 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK. (...) What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even i What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even if unprotected SI has occurred emergency contraception is not indicated. - Trip Database or use

2010 TRIP Answers

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>